Barry Quart, CEO of Heron Therapeutics, purchased 10,000 shares of Heron Therapeutics (Stock Symbol: HRTX) at $11.75 per share for a total amount of $117.5 thousand on June 25, 2014.
Heron Therapeutics is based in Redwood City, California.
On June 30th 2014, Heron Therapeutics announced closing of its underwritten public offering of 4,751,358 shares of common stock at a public offering price of $11.75 per share. As a component of the offering, in lieu of common stock, Heron Therapeutics, Inc. also offered and sold to certain existing large investors pre-funded warrants to purchase up to an aggregate of 600,000 shares of common stock at a purchase price of $11.74 per warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. Gross offering proceeds to Heron Therapeutics, Inc. are approximately $63 million before deducting underwriting discounts and commissions and offering expenses payable by Heron Therapeutics, Inc.
On May 8th 2014, Heron Therapeutics announced its latest quarterly results. As of March 31, 2014, we had approximately $57.5 million in cash, compared to $72.3 million as of December 31, 2013. Net cash used in operating activities was $15.7 million for the quarter ended March 31, 2014. Heron Therapeutics’ net loss for the first quarter of 2014 was $17.5 million, or $0.74 per share, compared to a net loss of $13.0 million, or $0.85 per share, for the first quarter of 2013.
According to Capital IQ, Heron Therapeutics has a market cap of 288.49 million, an enterprise value of 241.50 million, and no trailing 12 month revenues.
Heron Therapeutics, Inc., a specialty pharmaceutical company, develops product candidates using its proprietary Biochronomer polymer-based drug delivery platform. The companys drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that should be injected once or twice per day to products that need to be injected once every one or two weeks. Its lead product candidate, Sustol, is developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting for patients undergoing emetogenic chemotherapy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.
Barry Quart’s most recent annual compensation from Heron Therapeutics is a salary of $349,327, $7,906,890 in other compensation, and a total compensation of $8,256,210. Mr. Quart is 57 years old.
According to his biography, Dr. Barry D. Quart, Pharm.D., is Chief Executive Officer, Director of Heron Therapeutics, Inc. He has served as a member of the board of directors since June 2012. Dr. Quart was appointed Chief Executive Officer of the Company in May 2013. Until May 2013 Dr. Quart was President and Chief Executive Officer of Ardea Biosciences, a subsidiary of AstraZeneca PLC following its acquisition in June 2012, since its founding in December 2006. Previously, he was with Pfizer, Inc. as Senior Vice President, Pfizer Global Research and Development, and the Director of Pfizer’s La Jolla Laboratories. Prior to Pfizer’s acquisition of the Warner-Lambert Company, Dr. Quart was President of Research and Development at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company. Dr. Quart joined Agouron in 1993 and was instrumental in the development and registration of nelfinavir (Viracept®). Dr. Quart received his Pharm.D. from University of California, San Francisco.
All stories in DailyStocks.com are for informational purposes only. This is NOT a stock recommendation. This DailyStocks.com story is a daily light analysis featuring a stock with insider buying. With some caveats, insiders purchase a stock because they think the stock is going up. There are other factors to consider such as size of the transaction relative to their compensation and net worth. Sometimes, insiders might be propping a stock price up for future financing. Sometimes, the amount of insider buying are misread or misreported. Each month, DailyStocks releases a a summary of the stocks with insider buying. Sign up for the free monthly newsletter at DailyStocks.com .
About Dailystocks.com: DailyStocks.com is the place where you can find stories about stocks with insider buying, where you can educate yourself about stock market investing, and where you can perform the stock search engine analysis – you enter a stock symbol, and you get a resulting page of stock ticker indexed links so that you do not have to type the stock symbol each time.